Navigation Links
Basic Scientist Mark Roth Wins MacArthur Fellowship
Date:9/25/2007

Cell biologist receives $500,000 'genius award' with 'no strings attached'

SEATTLE, Sept. 25 /PRNewswire/ -- Mark Roth, Ph.D., a cell biologist at Fred Hutchinson Cancer Research Center, is among 24 recipients of this year's MacArthur Fellowships, a "genius" award given annually by the John D. and Catherine T. MacArthur Foundation. Roth will receive $500,000 over five years of "no-strings-attached" support.

Roth, a member of the Hutchinson Center's Basic Sciences Division, is perhaps best known for his research in reversible metabolic hibernation, a technique that one day may be used to help "buy time" for critically ill trauma patients on organ-transplant lists and in operating rooms, emergency rooms and battlefields.

"I'm just incredibly humbled and happy to be recognized by such a wonderful organization," said Roth, who has pursued a variety of research avenues, including studies on gene regulation, chromosome structure and function, autoimmune disease and, most recently, induced metabolic hibernation.

"The creative work I've been able to do has depended upon my interaction with people from vastly different scientific backgrounds -- people whose scientific orbits wouldn't normally intersect with mine. I'm hoping this fellowship will increase the possibility for more such creative collaborations," he said.

The MacArthur Fellowship Program was established in 1981 and includes 756 Fellows. In addition to Roth, those honored this year include a forensic anthropologist, a spider-silk biologist, a short-story writer, a nanotechnologist, a choreographer and a master vocalist, among others.

"As a group, this new class of Fellows takes one's breath away," said Daniel J. Socolow, director of the MacArthur Fellows Program, in a written statement. "As individuals, each is an original. To the person, they confirm that the creative individual is alive and well, at the cutting edge, and at work singularly and powerfully to make our world a better place. They are people who will change and influence our times."

Roth's work has led to major advances in basic biology, some of which have tremendous potential for human health. In particular, his research on induced metabolic hibernation, in which he has reversibly reduced the core temperature of mice to 10 degrees Celsius without loss of life or neurological problems, could one day lead to major breakthroughs for a host of human ills caused by tissue damage from a lack of oxygen.

"Mark is an exceptionally creative and innovative scientist who has pursued successfully more original avenues of research than anyone I know," said Roth's colleague Mark Groudine, M.D., Ph.D., a member of the Basic Sciences Division and deputy director of the Hutchinson Center. "In all cases, his rare ability to identify a seemingly intractable problem and tackle it with unswerving focus -- even when it required him to learn a completely new field, establish new collaborations, challenge conventional wisdom or develop new technology -- has led to major advances in basic biology, some of which have tremendous potential for human health. In particular, his new research on metabolic flexibility could lead to major breakthroughs in the treatment of stroke, trauma and cancer."

To help move this work forward into the clinical setting, Roth in 2005 founded a Seattle biotechnology company called Ikaria Inc., which earlier this year merged with INO Therapeutics to become Ikaria Holdings, a leader in the development of therapeutic gases for use in critical-care medicine. The company, based in Clinton, N.J., also operates a research and development facility in Seattle.

Earlier this year Roth received the 2007 Award for Significant Technical Achievement by the Defense Advanced Research Projects Agency, or DARPA, a major supporter of his work, for developing technology that "could dramatically improve the survival rate of wounded fighters and provide revolutionary improvements in the prevention and control of other medical complications on the battlefield."

Roth, who joined the Basic Sciences Division at the Hutchinson Center in 1989, is also an affiliate associate professor of biochemistry at the University of Washington. His numerous scientific articles have appeared in such publications as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology.

He received a bachelor of science in 1979 from the University of Oregon and a doctorate in 1984 from the University of Colorado at Boulder.

For more information about the MacArthur Fellowship Program, visit http://www.macfound.org.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

CONTACT

Kristen Woodward

(206) 667-5095

kwoodwar@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Basic Plasmid DNA Isolation Protocol
2. Basic Plasmid DNA Isolation Protocol
3. Array Analysis: The Basics
4. Northern Analysis: The Basics
5. Nuclease Protection Assays: The Basics
6. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
7. FERMENTATION BASICS
8. UW computer scientists fighting computer virus "Cold War"
9. UW scientist, former WiCell director found stem cell company
10. Scientists find way to make human collagen in lab
11. Wisconsin scientists to be recognized for innovative biofuel technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Germany on ... disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic total ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016  In five ... of Hematology (ASH) Annual Meeting and Exposition in ... biomedical engineering methods to improve the delivery of life-saving ... These new methods are designed to carry therapies directly ... needed most, which could provide a substantial advantage over ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):